Addition of rosiglitazone to existing sulfonylurea treatment in Chinese patients with type 2 diabetes and exposure to hepatitis B or C

Diabetes Technology and Therapeutics

Volumn 5, Issue 1, 2003, Pages 33-42

  Zhu, X X ^a   Chow, W H ^d   Pan, C Y ^b   Li, G W ^c   Shi, H L ^a   Tian, H ^b   Yang, W Y ^c   Jiang, J ^d   Sun, X C ^d   Davies, C ^d  

^a FUDAN UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c Sino Japan Friendship Hospital   (China)

^d GLAXOSMITHKLINE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PLACEBO; ROSIGLITAZONE; SULFONYLUREA;

ADULT; AGED; ARTICLE; CHINESE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FACE EDEMA; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HEPATITIS B; HEPATITIS C; HUMAN; HYPERLIPIDEMIA; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; LEG EDEMA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROPREVALENCE; THROMBOCYTOPENIA; TIME SERIES ANALYSIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VISUAL DISORDER; WEIGHT GAIN;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; CHINA; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENVIRONMENTAL EXPOSURE; FEMALE; GLICLAZIDE; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HEPATITIS B; HEPATITIS C; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; SULFONYLUREA COMPOUNDS; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0242501570     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/152091503763816445     Document Type: Article

References (18)

1. Whitcomb RW, Saltiel AR: Thiazolidinediones. Expert Opin Investig Drugs 1995;4:1299-1309.
2. Imura H: A novel antidiabetic drug, troglitazone - reason for hope and concern. N Engl J Med 1998;338:908-909.
3. Wolffenbuttel BHR, Gomist R, Squatrito S, Jones NP, Patwardhan RN: Addition of low-dose rosiglitazone to sulfonylurea therapy improves glycaemic control in Type 2 diabetic patients. Diabet Med 2000;17:40-47.
4. Narayan KMV, Gregg EW, Fagot-Campagna A, Engelgau MM, Vinicor F: Diabetes - a common, growing, serious, costly, and potentially preventable public health problem. Diabetes Res Clin Pract 2000;50(Suppl 2):S77-S84.
5. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039-1057.
6. Xixing Z, Changyu P, Guangwei L, Hongli S, Hui T, Wenying Y: Rosiglitazone improves glycemic control in Chinese patients with Type 2 diabetes mellitus in combination with sulphonylureas [abstract]. Diabetes 2001;50:A542.
7. Gómez-Perez FJ, Fanghänel-Salmón G, Antonio Barbosa J, Montes-Villarreal J, Berry RA, Warsi G, Gould EM: Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev 2002;18:127-134.
8. Barnett A: Rosiglitazone in type 2 diabetes: an evaluation in British Indo-Asian patients [abstract]. Diabet Med 2001;18:A40.
9. Gilbert RE, Cooper ME, Krum H: Drug administration in patients with diabetes mellitus. Drug Safety 1998;18(6):441-455.
10. Samraj GPN, Kuritzky L, Quillen DM: Improving management of type 2 diabetes mellitus: 5. Thiazolidinediones. Hosp Pract (Off Ed) 2000;35(1):123-124, 129-132.
11. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
12. UK Prospective Diabetes Study Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865.
13. Chaturvedi N, Fuller J: Mortality risk by body weight change in people with NIDDM: the WHO multinational study of vascular disease in diabetes. Diabetes Care 1995;18:766-774.
14. Watkins PB, Whitcomb RW: Hepatic dysfunction associated with troglitazone. N Engl J Med. 1998;338:916-917.
15. Scheen AJ: Hepatotoxicity with thiazolidinediones. Is it a class effect? Drug Safety 2001;24:873-888.
16. Erbey JR, Silberman C, Lydick E: Prevalence of abnormal serum alanine aminotransferase in obese patients with type 2 diabetes. Am J Med 2000;109:588-590.
17. Meltzer AA, Everhart JE: Association between diabetes and elevated serum alanine aminotransferase activity among Mexican Americans. Am J Epidemiol 1997;146:565-571.
18. Saltzman A: Rosiglitazone is not associated with hepatotoxicity [abstract 2]. Diabetologia 1999;42(Suppl 1):A3.